MSLN and hereditary clear cell renal cell carcinoma: Anti-mesothelin mAbs react with renal cell carcinomas and pancreatic and ovarian cancers [28–30], unlike the JMAM4 mAbs that did not react with lung, ovarian, or renal cell carcinomas or any of the other cancer cell lines tested.